Reviewers Commentary: This article adds to the growing body of literature on the role of PARP inhibitors in tumors with DNA repair defects.
Ruta Sahasrabudhe, PhD
Advertisement
Articles by Ruta Sahasrabudhe, PhD
Advertisement
Latest Updated Articles
Olaparib for Patients With DNA Repair Defects and Metastatic Prostate Cancer: Is it Time Yet?Published: April 23rd 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
